Trials / Completed
CompletedNCT01541423
A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema
A European Multi-Center, Multi-Country, Post-Authorisation, Observational Study (Registry) Of Patients With Hereditary Angioedema (HAE) Who Are Administered CINRYZE® (C1 Inhibitor [Human]) For The Treatment Or Prevention Of HAE Attacks
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 83 (actual)
- Sponsor
- Shire · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This observational (non-interventional) study is being conducted to characterize the safety and use of CINRYZE in routine clinical practice when administered for (1) routine prevention of angioedema attacks, (2) pre-procedure prevention of angioedema attacks, and/or (3) treatment of angioedema attacks.
Conditions
Timeline
- Start date
- 2012-05-11
- Primary completion
- 2016-09-25
- Completion
- 2016-09-25
- First posted
- 2012-03-01
- Last updated
- 2021-03-17
Locations
20 sites across 6 countries: Belgium, France, Germany, Italy, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT01541423. Inclusion in this directory is not an endorsement.